Nicholas Grund Biography and Net Worth

Insider of Akebia Therapeutics

Nicholas Grund joined Akebia in January 2024 as Senior Vice President, Chief Commercial Officer. Prior to joining Akebia, Mr. Grund served as the President of Eurofins Transplant Genomics from January 2021 to November 2022. From May 2019 to December 2020, Mr. Grund was the owner and consultant of NG Strategy Consulting. Prior to NG Strategy Consulting, Mr. Grund served as the Chief Commercial Officer of AMAG Pharmaceuticals, Inc. from January 2016 to March 2019. Prior to joining AMAG, Mr. Grund served from 2002 to 2015 in various positions of increasing responsibility at Genzyme Corporation, a Sanofi company (“Genzyme”), where he was Head of Specialty Care. Prior to Genzyme, Mr. Grund progressed through a number of senior finance roles in the Critical Care Business Unit of Bayer Diagnostics from 1995 to 2002. Mr. Grund holds an M.B.A. from Northeastern University and a B.S. in business administration from the University of Massachusetts.

What is Nicholas Grund's net worth?: The estimated net worth of Nicholas Grund is at least $703.70 thousand as of February 3rd, 2025. Grund owns 442,579 shares of Akebia Therapeutics stock worth more than $703,701 as of December 5th. This net worth approximation does not reflect any other assets that Grund may own. Learn More about Nicholas Grund's net worth.
How old is Nicholas Grund?: Grund is currently 54 years old. There are 4 older executives and no younger executives at Akebia Therapeutics. The oldest executive at Akebia Therapeutics is Dr. Steven Keith Burke M.D., Senior VP of Research & Development and Chief Medical Officer, who is 63 years old. Learn More on Nicholas Grund's age.
How do I contact Nicholas Grund?: The corporate mailing address for Grund and other Akebia Therapeutics executives is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. Akebia Therapeutics can also be reached via phone at (617) 871-2098 and via email at [email protected]. Learn More on Nicholas Grund's contact information.
Has Nicholas Grund been buying or selling shares of Akebia Therapeutics?: Nicholas Grund has not been actively trading shares of Akebia Therapeutics during the last quarter. Most recently, Nicholas Grund sold 55,621 shares of the business's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $2.10, for a transaction totalling $116,804.10. Following the completion of the sale, the insider now directly owns 442,579 shares of the company's stock, valued at $929,415.90. Learn More on Nicholas Grund's trading history.
Who are Akebia Therapeutics' active insiders?: Akebia Therapeutics' insider roster includes Steven Burke (SVP), John Butler (CEO), Violetta Cotreau (CAO), Michel Dahan (COO), Steven Gilman (Director), Nicholas Grund (Insider), Richard Malabre (CAO), Erik Ostrowski (Senior Vice President, Chief Financial Officer & Chief Business Officer), and David Spellman (CFO). Learn More on Akebia Therapeutics' active insiders.
Are insiders buying or selling shares of Akebia Therapeutics?: During the last twelve months, insiders at the biopharmaceutical company sold shares 7 times. They sold a total of 350,227 shares worth more than $848,057.30. The most recent insider tranaction occured on June, 30th when CFO Erik Ostrowski sold 41,314 shares worth more than $151,622.38. Insiders at Akebia Therapeutics own 3.0% of the company. Learn More about insider trades at Akebia Therapeutics.
Information on this page was last updated on 6/30/2025.

Nicholas Grund Insider Trading History at Akebia Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/3/2025	Sell	55,621	$2.10	$116,804.10	442,579

Nicholas Grund Buying and Selling Activity at Akebia Therapeutics

Akebia Therapeutics Company Overview

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $1.59

$1.53

$1.61

50 Day Range

MA: $2.29

$1.47

$3.17

2 Week Range

Now: $1.59

$1.45

$4.08

Volume

1,995,511 shs

Average Volume

4,952,545 shs

Market Capitalization

$421.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.31

Nicholas Grund Biography and Net Worth

What is Nicholas Grund's net worth?

How old is Nicholas Grund?

How do I contact Nicholas Grund?

Has Nicholas Grund been buying or selling shares of Akebia Therapeutics?

Who are Akebia Therapeutics' active insiders?

Are insiders buying or selling shares of Akebia Therapeutics?